Translating the genome into individualized therapeutics

Drug Development Research

Volumn 62, Issue 4, 2004, Pages 371-382

  Lavedan, Christian ^a   Birznieks, Gunther ^a   Dressman, Marlene ^a   McCullough, Karen ^a   Paczkowski, Rebecca ^a   Torres, Rosa ^a   Wolfgang, Curt ^a   Polymeropoulos, Mihael ^a  

^a Vanda Pharmaceuticals Inc   (United States)

Author keywords

Drug; Genetic; Genomic; Microarray; Polymorphism

Indexed keywords

ATOMOXETINE; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; CYTOCHROME P450; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE 2 RECEPTOR; FEXOFENADINE; FLUOXETINE; HYDRALAZINE; IMATINIB; IRINOTECAN; ISONIAZID; LOSARTAN; MERCAPTOPURINE; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; NEUROLEPTIC AGENT; NORTRIPTYLINE; OMEPRAZOLE; PHENYTOIN; PROCAINAMIDE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; SUXAMETHONIUM; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN;

ATTENTION DEFICIT DISORDER; BIOINFORMATICS; BLEEDING; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TRANSPORT; FATTY LIVER; GENE EXPRESSION PROFILING; GENE TECHNOLOGY; GENETIC LINKAGE; GENETIC RISK; GENOME; HUMAN; LINKAGE ANALYSIS; LIVER TOXICITY; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; QUALITY OF LIFE; REVIEW; RNA TRANSLATION; SIDE EFFECT; TOXICOGENETICS; TREATMENT OUTCOME;

EID: 11344276183     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10390     Document Type: Review

References (81)

1. Aithal GP, Day CP, Kesteven PJ, Daly AK. 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719.
2. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P, Kerwin R. 1995. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346:281-282.
3. Aune TM, Maas K, Parker J, Moore JH, Olsen NJ. 2004. Profiles of gene expression in human autoimmune disease. Cell Biochem Biophys 40:81-96.
4. Ben Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. 1986. The chronic myelogenous leukemia-specific P210 protein is the product of the Bcr/Abl hybrid gene. Science 233:212-214.
5. Buchdunger E, O'Reilly T, Wood J. 2002. Pharmacology of imatinib (STI571). Eur J Cancer 38(suppl 5):S28-S36.
6. Chalon SA, Desager JP, Desante KA, Frye RF, Witcher J, Long AJ, Sauer JM, Golnez JL, Smith BP, Thomasson HR, Horsmans Y. 2003. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 73:178-191.
7. Clark GM, McGuire WL. 1988. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15(suppl 1):20-25.
8. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Halnes JL, Pericak-Vance MA. 1993. Gene dose of apollpoprotein E type 4 allele and the risk of Alzheilmer's disease in late onset families. Science Aug 13;261(5123):921-923.
9. Cowan-Jacob SW, Guez V, Fendrich G, Griffin JD, Fabbro D, Furet P, Liebetanz J, Mestan J, Manley PW. 2004. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 4:285-299.
10. Dahl ML, Bertilsson L. 1993. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3:61-70.
11. Dalen P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L. 1998. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63:444-452.
12. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR. 1982. A cellular oncogene is translocated to the Philadelphia chromosome in chrome myelocytic leukaemia. Nature 300:765-767.
13. De Lange R, Burtscher H, Jarsch M, Weidle UH. 2001. Identification of metastasis-associated genes by transcriptional profiling of metastatic versus non-metastatic colon cancer cell lines. Anticancer Res 21:2329-2339.
14. De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. 1994. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422.
15. Dimasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: new estimates of drug development costs. J Health Econ. Mar;22(2):151-185.
16. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, Wood AJ. 2001. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 345:1030-1035.
17. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman ES, Katz DA, Drajesk J. 1999. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 22:168-170.
18. Dressman MA, Walz TM, Lavedan C, Barnes L, Buchholtz S, Kwon I, Ellis MJ, Polymeropoulos MH. 2001. Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies. Pharmacogenomics J 1:135-141.
19. Dressman MA, Baras A, Malinowski R, Alvis LB, Kwon I, Walz TM, Polymeropoulos MH. 2003. Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. Cancer Res 63:2194-2199.
20. Dressman MA, Malinowski R, McLean LA, Gathmann I, Capdeville R, Hensley M, Polymeropoulos MH. 2004. Correlation of major cvtogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571). Clin Cancer Res 10:2265-2271.
21. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042.
22. Evans WE, Johnson JA. 2001. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2:9-39.
23. Evans WE, McLeod HL. 2003. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 348:538-549.
24. Evans WE, Relling MV. 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
25. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36.
26. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E. 1998. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129:1027-1030.
27. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J. 2001. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-548.
28. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
29. Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, Heber D. 2003. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 22:663-670.
30. The Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
31. Ingelman-Sundberg M, Oscarson M, McLellan RA. 1999. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342-349.
32. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. 2002. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47.
33. Jacobsen P, Rossing K, Rossing P, Tarnow L, Mallet C, Poirier O, Cambien F, Parving HH. 1998. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 53:1002-1006.
34. Jarvinen TA, Liu ET 2003. HER-2/Neu and topoisomerase II alpha in breast cancer. Breast Cancer Res Treat 78:299-311.
35. Jung M, Kim H, Kim M. 2003. Chemical genomics strategy for the discovery of new anticancer agents. Curr Med Chem 10:757-762.
36. Kalow W. 1990. The Pennsylvania State University College of Medicine 1990 Bernard B. Brodie Lecture. Pharmacogenetics: past and future. Life Sci 47:1385-1397.
37. Kalow W, Gunn DR. 1959. Some statistical data on atypical cholinesterase of human serum. Ann Hum Genet 23:239-250.
38. Kanehisa M, Goto S. 2000. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27-30.
39. Kauraniemi P, Barlund M, Monni O, Kallioniemi A. 2001. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by CDNA microarrays. Cancer Res 61:8235-8240.
40. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. 2001. Identification of functionally-variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199.
41. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH. 2002. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 159:1593-1595.
42. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. 1990. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225-229.
43. Lennard L, Van Loon JA, Weinshilboum RM. 1989. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 46:149-154.
44. Litherland S, Jackson IM. 1988. Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev 15:183-194.
45. Lonning PE, Sorlie T, Perou CM, Brown PO, Botstein D, Borresen-Dale AL. 2001. Microarrays in primary breast cancer - lessons from chemotherapy studies. Endocr Relat Cancer 8:259-263.
46. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780-796.
47. McLean LA, Gathmann I, Capdeville R, Polymeropoulos MH, Dressman M. 2004. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 10:155-165.
48. McLeod HL, Evans WE. 2001, Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41:101-121.
49. Motulsky AG. 1957. Drug reactions enzymes, and biochemical genetics. J Am Med Assoc 165:835-837.
50. Napolitano C, Schwartz PJ, Brovvn AM, Ronchetti E, Bianchi L, Pinnavaia A, Acquaro G, Priori SG. 2000. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 11:691-696.
51. Nowell PC, Hungerford DA, 1960. A minute chromosome in human chronic granulocytic leukemia. Science 132:1497.
52. Ongphiphadhanakul B, Chanprasertyothin S, Payatikul P, Tung SS, Piaseu N, Chailurkit L, Chansirikarn S, Puavilai G, Rajatanavin R. 2000. Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin Endocrinol (Oxf) 52:581-585.
53. Ott J. 1995. Linkage analysis with biological markers. Hum Hered 45:169-174.
54. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406:747-752.
55. Poirier J, Davignon J, Bouthiller D, Kogan S, Bertrand P, Gauthier S. 1993. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet Sep 18;342(8873):697-699.
56. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 92:12260-12264.
57. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinsons disease. Science 276:2045-2047.
58. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. 1996. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 51:289-295.
59. Prakash O, Yunis JJ. 1984. High resolution chromosomes of the T(9;22) positive Ieukemias. Cancer Genet Cytogenet 11:361-367.
60. Price WJ, Holley DC. 1990. Shiftwork and safety in aviation. Occup Med 5:343-377.
61. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, Siscovick DS, Bis J, Lumley T, Longstreth WT Jr, Rosendaal FR. 2002. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 287:1680-1689.
62. Reidenberg MM, Drayer DE, Levy M, Warner H. 1975. Polymorphic acetylation procainamide in man. Clin Pharmacol Ther 17:722-730.
63. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066-1073.
64. Rowley JD. 1973. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-293.
65. Salemme FR. 2003. Chemical genomics as an emerging paradigm for postgenomic drug discovery. Pharmacogenomics 4:257-267.
66. Sallee FR, DeVane CL, Ferrell RE. 2000. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 10:27-34.
67. Schafer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, Moller HJ. 2001. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 158:802-804.
68. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL Jr, Goldstein SA. 2000. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 97:10613-10618.
69. Shtivelman E, Lifshitz B, Gale RP, Canaani E. 1985. Fused transcript of Abl and Bcr genes in chronic myelogenous leukaemia. Nature 315:550-554.
70. Siest G, Bertrand P, Herbeth B, Vincent-Viry M, Schiele F, Sass C, Visvikis S. 2000. Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. Clin Chem Lab Med 38:841-852.
71. Smith IE. 2001. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs 12(suppl 4):S3-S10.
72. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874.
73. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. 1996. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429-439.
74. Suter L, Haiker M, De Vera MC, Albertini S. 2003, Effect of two 5-HT(6) receptor antagonists on the rat liver: a molecular approach. Pharmacogenomics J 3:320-334.
75. Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Kasuga M, Okumura K. 1999. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 66:528-534.
76. Timbrell JA, Harland SJ, Facchini V. 1980. Polymorphic acetylation of hydralazine. Clin Pharmacol Ther 28:350-355.
77. Tollman P, Guy P, Altshuler J, Flanagan A, Steiner M. A revolution in R&D; how genomics and genetics are transforming the biopharmaceutical industry. www.bcg.com. 2001.
78. Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich RG. 2001. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol Lett 120:359-368.
79. Weinshilboum R. 2003. Inheritance and drug response. N Engl J Med 348:529-537.
80. Weinshilboum RM, Otterness DM, Szumlanski CL. 1999. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39:19-52.
81. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. 1997. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608-614.